Ireland
--:--IST
Recruiting Observational

SL-START - SubLingual Apomorphine Schemes of TitrAtion in Real-world Treatment

NCT07145190 · tracked via the Priya Life Science Germany tracker
Sponsor
Bial - Portela C S.A
Phase
Observational
Started
2025-08-27
Last updated
2026-08-11

Condition(s) studied

Parkinson Disease

Investigational drug(s) / intervention(s)

SL-APO

SL-APO: Patients should start with a dose of 10 mg SL-APO. Dose initiation should occur when the patient is having an OFF episode. If the patient tolerates the 10 mg dose, and responds adequately (meaning satisfactory motor response within 30 minutes), the maintenance dose should be 10 mg. If the dose is tolerated but the response is insufficient, continue to titrate in 5 mg increments when the patient is having an OFF episode and assess response until an effective and tolerable dose is achieved, up to a maximum of 30 mg per dose and up to five times a day. If an "ON" response is achieved and if clinically warranted, consider the need to further up-titrate as tolerated to achieve a better "ON" response. The minimal interval between doses is 2 hours, with no more than one dose of SL-APO per OFF episode.

Study summary

The purpose of the study is to generate real-world evidence data for the on-demand treatment with SL-APO, focusing on understanding its usage and titration practices including individual dose determination after dose-adjustment to ultimately understand their influence in patient satisfaction, treatment persistence, and the balance between effectiveness and safety. The data may help optimize titration approaches to better meet the patient's needs.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * The patient is ≥ 18 years of age. * The patient has a clinical diagnosis of idiopathic Parkinson's disease. * The patient will initiate SL-APO for the treatment of OFF episodes according to the SmPC. * The patient is not currently on titration or maintenance dose for SL-APO. * The patient has provided written informed consent to participate in this study. Exclusion Criteria: * The patient is participating in a clinical trial with an investigational drug. * The patient has presented with dementia or evidence of cognitive decline as determined by the investigator. * The patient has a history of psychotic disorder. * The patient presents any other contraindication according to the SL-APO SmPC.

Primary outcome measure(s)

  • Identify the most frequent dose used after dose-adjustment — Up to 6 months
    The purpose of the study is to generate real-world evidence data for the on-demand treatment with SLAPO, focusing on understanding its usage and titration practices including individual dose determination after dose-adjustment to ultimately understand their influence in patient satisfaction, treatment persistence, and the balance between effectiveness and safety. The data may help optimize titration approaches to better meet the patient's needs.

Trial sites (12)

FacilityCityRegionStatus
Charité - Universitätsmedizin Berlin - Sektion für Bewegungsstörungen und Neuromodulation Berlin Germany Recruiting
Alexianer St. Joseph Berlin-Weißensee GmbH Berlin Germany Suspended
Praxis für Neurologie Berlin Germany Recruiting
Katholisches Klinikum Bochum gGmbH, Universitätsklinikum St.Josef-Hospital, Klinik für Neurologie Bochum Germany Not Yet Recruiting
UNIVERSITÄTSKLINIKUM FREIBURG - Neurozentrum Klinik für Neurologie und Neurophysiologie im Neurozentrum Freiburg im Breisgau Germany Recruiting
Praxis für Neurologie und Psychiatrie Fulda Germany Recruiting
Klinik am Tharandter Wald Hetzdorf Germany Recruiting
Klinik für Neurologie und Neurologische Frührehabilitation Osnabrück Germany Recruiting
Die Nerven Docs Siegen Germany Recruiting
Neurologische Klinik Sorpesee Sundern Germany Recruiting
Praxis für Neurologie und Geriatrie Ulm Germany Recruiting
Neurologie am Funkerberg Wusterhausen Germany Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07145190 on ClinicalTrials.gov ↗ ← All trials in Germany